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MaBACKGROUND Acute ischemic stroke is a leading cause of serious disability and death worldwide. Individual
randomized trials have shown possible beneﬁts of mechanical thrombectomy after usual care compared with usual
care alone (i.e., intravenous thrombolysis) in the management of acute ischemic stroke patients.
OBJECTIVES This study systematically determined if mechanical thrombectomy after usual care would be associated
with better outcomes in patients with acute ischemic stroke caused by large artery occlusion.
METHODS The authors included randomized trials that compared mechanical thrombectomy after usual care versus
usual care alone for acute ischemic stroke. Random effects summary risk ratios (RR) were constructed using a
DerSimonian and Laird model.
RESULTS Nine trials with 2,410 patients were available for analysis. Compared with usual care alone, mechanical
thrombectomy was associated with a higher incidence of achieving good functional outcome, deﬁned as a modiﬁed Rankin
scale (mRS) of 0 to 2 (RR: 1.45; 95% conﬁdence interval [CI]: 1.22 to 1.72; p < 0.0001) and excellent functional outcome
deﬁned as mRS 0 to 1 (RR: 1.67; 95% CI: 1.27 to 2.19; p < 0.0001) at 90 days. There was a trend toward reduced all-cause
mortality with mechanical thrombectomy (RR: 0.86; 95% CI: 0.72 to 1.02; p ¼ 0.09). The risk of symptomatic intracranial
hemorrhage was similar with either treatment modality (RR 1.06: 95% CI: 0.73 to 1.55; p ¼ 0.76).
CONCLUSIONS In acute ischemic stroke due to large artery occlusion, mechanical thrombectomy after usual care was
associated with improved functional outcomes compared with usual care alone, and was found to be relatively safe, with
no excess in intracranial hemorrhage. Therewas a trend for reduction in all-causemortalitywithmechanical thrombectomy.
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AB BR E V I A T I O N S
AND ACRONYM S
CI = conﬁdence interval
mRS = modiﬁed Rankin scale
OR = odds ratio
RR = risk ratio
sICH = symptomatic
intracranial hemorrhage
tPA = tissue plasminogen
activator
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2499D espite advances in medical therapy, acuteischemic stroke remains a leading cause ofserious disability and death worldwide
(1,2). Intravenous tissue plasminogen activator (tPA)
remains the only effective reperfusion therapy if
administered in a timely manner (<4.5 h) (3–6). Unfor-
tunately, only 21% of patients achieve effective recan-
alization with intravenous tPA even when
administered within this ischemic window (7). Intra-
arterial therapy was developed as a means to improve
vessel recanalization. Intra-arterial thrombolysis for
large-vessel occlusion was ﬁrst described in the
1980s (8), and formally evaluated in the PROACT II
(Prolyse in Acute Cerebral Thromboembolism) trial,
which showed better outcomes with intra-arterial uro-
kinase versus intravenous heparin alone (9).SEE PAGE 2506In contrast, subsequent trials that used ﬁrst-
generation thrombectomy devices failed to demon-
strate clinical beneﬁt compared with intravenous
thrombolysis (10,11). An important cause of failure for
those early mechanical thrombectomy devices was
thought to be the lower rate of recanalization achieved
with these devices (12). However, newer-generation
retrievable stents achieve higher recanalization rates
compared with ﬁrst-generation thrombectomy de-
vices (13,14). Because this ﬁeld has undergone rapid
development, the clinical utility of these devices for
reducing mortality and morbidity in acute ischemic
stroke remains uncertain. Accordingly, we performed
a comprehensive meta-analysis to evaluate the efﬁ-
cacy and safety of mechanical thrombectomy after
usual care versus usual care alone.
METHODS
A computerized search of the Medline database,
without language restriction, was performed from
inception until May 2015 using the strategy illus-
trated in Online Figure 1. In addition, the Web of
Science and Cochrane Register of Controlled Trials
were searched using the key words “stroke,”
“thrombectomy,” and “arterial thrombolysis.” Ab-
stracts of the major scientiﬁc sessions from January
2013 to April 2015 (International Stroke Organiza-
tion, European Stroke Organization Conference,
and the American Heart Association) were also
searched with the same key words. Furthermore,
the reference lists of the retrieved articles and
previous meta-analyses were reviewed (15–18). The
planned analysis was registered at the International
Prospective Register for Systematic Reviews or
PROSPERO (CRD42015019201).SELECTION CRITERIA AND DATA EXTRACTION.
Trials that randomized acute ischemic stroke
patients within 4.5 h of symptom onset
and who received usual care were random-
ized to undergo mechanical thrombectomy
versus no mechanical thrombectomy were
included. For usual care, most patients
received intravenous thrombolysis, unless
there were contraindications or an extended
time window. Trials that prohibited intrave-
nous thrombolysis before mechanical throm-
bectomy were excluded.
Data on study design, sample characteristics,
sample size, intervention strategies, outcomes, and
other study characteristics from the selected studies
were extracted by 2 independent investigators (I.Y.E.
and A.M.). Discrepancies were resolved by consensus
of the investigators. For all clinical outcomes, the
number of events that occurred in each arm of each
trial was tabulated.
OUTCOMES AND DEFINITIONS. The modiﬁed Rankin
scale (mRS) is a widely accepted and objective tool to
measure post-stroke functional outcome and has
been used in most of the major acute ischemic stroke
trials, with scores ranging from 0 (fully independent
without deﬁcit) to 6 (death). We deﬁned excellent
functional outcome as mRS 0 to 1, good functional
outcome as mRS 0 to 2, and fair functional outcome as
mRS 0 to 3 (19). Our primary outcome of interest was
good functional outcome at 90 days. The secondary
efﬁcacy outcomes assessed were all-cause mortality,
excellent functional outcome, fair functional out-
come, and recanalization as deﬁned by the individual
studies. The safety outcomes evaluated were symp-
tomatic intracranial hemorrhage (sICH) (range: 27 h to
7 days) and recurrent stroke.
STATISTICAL ANALYSIS. Outcomes were analyzed
by intention-to-treat analysis. Random effects sum-
mary risk ratios (RRs) were constructed using a
DerSimonian and Laird model (20). Fixed-effects
summary odds ratios (ORs) were performed using
Peto’s model (21). Statistical heterogeneity was
examined using the I2 statistic, with I2 statistic
values <25%, 25% to 50%, and >50% considered as
low, moderate, and high degree of heterogeneity,
respectively (22). The method of Egger (23) was used
to calculate the risk of publication bias. This meta-
analysis was conducted in concordance with the
Preferred Reporting Items for Systematic Reviews
and Meta-Analyses guidelines (24). The quality of the
trials was evaluated on the basis of the adequate
description of treatment allocation, blinded outcome
assessment, and description of losses to follow-up
(25). All p values were 2-tailed, with statistical
TABLE 1 Baseline Characteristics and Treatment Strategies
Study (Ref. #) Year n*
Age*
(yrs)
Male*
(%) NIHSS*
Time to
Mechanical
Thrombectomy
IV
Thrombolysis*
(%)
Time to IV
Thrombolysis*
Major Artery
Occlusion Documented
Before Inclusion?
MR RESCUE: penumbral (26) 2013† 34/34 66  13/66  17 50/44 NR† NR† 47/26 NR† Yes
MR RESCUE: non-penumbral (26) 30/20 62  12/69  16 43/60 40/35
IMS III (10) 2013 434/222 69/68 50/55 17/16 208‡§ 100/100 122/121 No
MR CLEAN (27) 2015 233/267 66/66 58/59 17/18 260§ 87/91 85/87 Yes
ESCAPE (28) 2015 165/150 71/70 48/47 16/17 241 73/79 110/125 Yes
EXTEND-IA (29) 2015 35/35 69  12/70  12 49/49 17/13 248 100/100 127/145 Yes
SWIFT PRIME (30) 2015 98/98 65  13/66  11 55/47 17/17 252 100/100 161/168 Yes
REVASCAT (31) 2015 103/103 66  11/67  10 53/52 17/17 355 68/78 118/105 Yes
THERAPY (32) 2015 41/41 NR NR NR 226 NR NR Yes
THRACE (33) 2015 190/195 62k NR 17k 225 NR NR Yes
Values are mean  SD unless otherwise indicated. *Values are presented for medical thrombectomy/usual care alone groups. †Data for both subgroups in this study were combined together. ‡Mean was
reported. §Time to groin puncture was reported. kData were reported as combined for both arms.
ESCAPE¼ Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on Minimizing CT to Recanalization Times; EXTENDA-IA ¼ Extending the Time for Thrombolysis
in Emergency Neurological Deﬁcits–Intra-arterial; IMS III ¼ Third Interventional Management of Stroke; IV ¼ intravenous; MR CLEAN ¼ Multicenter Randomized Clinical Trial of Endovascular Treatment for
Acute Ischemic Stroke in the Netherlands; MR RESCUE ¼Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy; NIHSS ¼ National Institutes of Health Stroke Scale; NR ¼ not reported;
REVASCAT¼ Randomized Trial of Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior Circulation Large Vessel Occlusion Presenting within
Eight Hours of Symptom Onset; SWIFT PRIME ¼ Solitaire FR With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke; THERAPY ¼ Randomized, Concurrent
Controlled Trial to Assess the Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke; THRACE ¼ Trial and Cost Effectiveness Evaluation of Intra-arterial Thrombectomy in Acute
Ischemic Stroke.
TABLE 2 Measures o
Study (Ref. #)
MR RESCUE (26) M
IMS III (10) M
MR CLEAN (27) M
ESCAPE (28) M
EXTEND-IA (29) M
SWIFT PRIME (30) M
REVASCAT (31) M
THERAPY (32) M
THRACE (33) M
Values are presented for m
ESCAPE¼ Endovascular
Minimizing CT to Recanaliz
Elgendy et al. J A C C V O L . 6 6 , N O . 2 2 , 2 0 1 5
Mechanical Thrombectomy in Stroke D E C E M B E R 8 , 2 0 1 5 : 2 4 9 8 – 5 0 5
2500signiﬁcance set at p < 0.05, and conﬁdence intervals
(CIs) were calculated at the 95% level for the overall
estimates effect. All analyses were performed using
STATA software version 11 (StataCorp, College Sta-
tion, Texas).
A pre-speciﬁed analysis was conducted excluding
unpublished trials, and another was performed
excluding trials that tested other modalities of endo-
vascular therapy aside from mechanical thrombectomyf Study Quality
Single/
Multicenter
Blinded
Endpoint
Generation of
Treatment
Assignment
Follow-Up
Completion
(%)
Primary
Outcome
ulticenter Yes Centralized website 100/100 mRS
ulticenter Yes Sealed envelope 100/100 mRS 0–2
ulticenter Yes Centralized website 100/100 mRS
ulticenter Yes Centralized website 99/98 mRS
ulticenter Yes Centralized website 100/100 mRS 0–1
ulticenter Yes Interactive web
response or
interactive
voice
response
system
100/95 mRS 0–2
ulticenter Yes Real-time
computerized
randomization
procedure
100/100 mRS
ulticenter NR NR NR mRS 0–2
ulticenter NR NR NR mRS 0–2
echanical thrombectomy/intravenous thrombolysis groups.
Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on
ation Times; mRS ¼ modiﬁed Rankin scale; other abbreviations as in Table 1.(i.e., intra-arterial thrombolysis). Random effects meta-
regression analyses were pre-speciﬁed for the primary
outcome with time to mechanical thrombectomy and
publication year.
RESULTS
Overall, 9 trials met our inclusion criteria, with a
total of 2,410 patients (10,26–33). Seven studies were
retrieved from Medline (10,26–31), and 2 studies
were presented at the European Stroke Organization
Conference (32,33). Retrievable stents were man-
dated in 3 studies (29–31), encouraged in 2 studies
(27,28), and allowed in 2 other studies (10,26). The
THERAPY trial (Randomized, Concurrent Controlled
Trial to Assess the Penumbra System’s Safety and
Effectiveness in the Treatment of Acute Stroke)
tested an aspiration thrombectomy device (32). In 3
trials—MR RESCUE (Mechanical Retrieval and
Recanalization of Stroke Clots Using Embolectomy),
IMS III (Third Interventional Management of Stroke)
trial, and MR CLEAN (Multicenter Randomized Clin-
ical Trial of Endovascular Treatment for Acute
Ischemic Stroke in the Netherlands)—intra-arterial
thrombolysis could be given alone or in combination
with mechanical thrombectomy (10,26,27). Intrave-
nous tPA was the sole thrombolytic agent used in all
the studies, except for MR CLEAN, which also
allowed intravenous urokinase (27). The occluded
arteries were mainly the internal carotid artery, and
the M1 and M2 segments of the middle cerebral ar-
tery. The follow-up duration in all the included
FIGURE 1 Summary Plot: Good Functional Outcome
Study
ID RR (95% CI)
%
Weight
MR RESCUE penumbral
MR RESCUE non–penumbral
IMS III
MR CLEAN
ESCAPE
EXTENDA–IA
SWIFT PRIME
REVASCAT
THERAPY
THRACE
Overall (I–squared = 54.0%, p = 0.021)
0.63 (0.23, 1.72)
1.00 (0.18, 5.46)
1.05 (0.86, 1.29)
1.71 (1.25, 2.32)
1.84 (1.38, 2.46)
1.79 (1.13, 2.82)
1.79 (1.30, 2.46)
1.55 (1.06, 2.27)
1.33 (0.72, 2.46)
1.29 (1.04, 1.59)
1.45 (1.22, 1.72)
2.52
0.97
16.79
12.77
13.38
8.53
12.33
10.54
5.76
16.41
100.00
NOTE: Weights are from random effects analysis
.1 1 10
Mechanical Thrombectomy Associated with Worse mRS 0–2 Mechanical Thrombectomy Associated with Better mRS 0–2
More patients who had mechanical thrombectomy after usual care achieved a higher incidence of achieving good functional outcome (modiﬁed
Rankin scale [mRS] 0 to 2) compared with usual care alone. The relative size of the data markers indicates the weight of each study’s sample
size. CI ¼ conﬁdence interval; ESCAPE ¼ Endovascular Treatment for Small Core and Anterior Circulation Proximal Occlusion with Emphasis on
Minimizing CT to Recanalization Times; EXTENDA-IA ¼ Extending the Time for Thrombolysis in Emergency Neurological Deﬁcits–Intra-arterial;
IMS III ¼ Third Interventional Management of Stroke; MR CLEAN ¼ Multicenter Randomized Clinical Trial of Endovascular Treatment for Acute
Ischemic Stroke in the Netherlands; MR RESCUE ¼ Mechanical Retrieval and Recanalization of Stroke Clots Using Embolectomy; REVASCAT ¼
Randomized Trial of Revascularization with Solitaire FR Device versus Best Medical Therapy in the Treatment of Acute Stroke Due to Anterior
Circulation Large Vessel Occlusion Presenting within Eight Hours of Symptom Onset; RR ¼ risk ratio; SWIFT PRIME ¼ Solitaire FR With the
Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke; THERAPY ¼ Randomized, Concurrent Controlled
Trial to Assess the Penumbra System’s Safety and Effectiveness in the Treatment of Acute Stroke; THRACE ¼ Trial and Cost Effectiveness
Evaluation of Intra-arterial Thrombectomy in Acute Ischemic Stroke.
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2501studies was 90 days. Baseline characteristics and
treatment strategies of these studies are listed in
Table 1, whereas Table 2 lists the measures of study
quality. Two studies have not yet been published;
therefore information regarding treatment allocation
and blinded endpoint assessment was lacking (32,33);
the remaining studies were classiﬁed as having a low
risk for bias.
PRIMARY OUTCOME. Mechanical thrombectomy af-
ter usual care was associated with a higher incidence
of achieving good functional outcome (mRS 0 to 2) at
90 days compared with usual care alone (43.7% vs.
30.9%; RR: 1.45; 95% CI: 1.22 to 1.72; p < 0.0001) with
no evidence of publication bias using the test by
Egger et al. (23) (p ¼ 0.74) (Figure 1). Findings from
the pre-speciﬁed analyses yielded similar results:
1) excluding unpublished trials (RR: 1.49; 95% CI: 1.20
to 1.87, p < 0.0001); and 2) excluding trials thatallowed intra-arterial thrombolysis (MR RESCUE, IMS
III, and MR CLEAN: RR: 1.55; 95% CI: 1.35 to 1.79;
p < 0.0001). Meta-regression analysis revealed better
outcomes with recent publication year (p ¼ 0.02),
but did not identify a difference in treatment
effect on the basis of time to mechanical thrombec-
tomy (p ¼ 0.28).
SECONDARY OUTCOMES. At 90 days, mechanical
thrombectomy after usual care was associated with
a trend toward reduction in the risk of all-cause
mortality compared with usual care alone (15.9%
vs. 17.9%; RR: 0.86; 95% CI: 0.72 to 1.02; p ¼ 0.09)
(Figure 2). A similar trend was observed after
excluding the trials that allowed intra-arterial
thrombolysis (MR RESCUE, IMS III, and MR
CLEAN) (RR: 0.77; 95% CI: 0.57 to 1.03; p ¼ 0.08).
Mechanical thrombectomy after usual care was
associated with a higher incidence of achieving both
FIGURE 2 Summary Plot: All-Cause Mortality
Study
ID RR (95% CI) Weight
%
MR RESCUE penumbral
MR RESCUE non–penumbral
IMS III
MR CLEAN
ESCAPE
EXTENDA–IA
SWIFT PRIME
REVASCAT
THERAPY
THRACE
Overall (I–squared = 0.0%, p = 0.608)
0.86 (0.32, 2.29)
0.67 (0.25, 1.78)
0.88 (0.64, 1.21)
1.03 (0.71, 1.49)
0.55 (0.32, 0.97)
0.43 (0.12, 1.52)
0.75 (0.33, 1.70)
1.19 (0.65, 2.18)
0.50 (0.19, 1.34)
0.95 (0.56, 1.59)
0.86 (0.72, 1.02)
3.22
3.23
30.94
22.98
9.86
1.93
4.64
8.43
3.21
11.57
100.00
NOTE: Weights are from random effects analysis
.1 1 10
Mechanical Thrombectomy Associated with Lower Incidence of
All–Cause Mortality
Mechanical Thrombectomy Associated with Increased Incidence
of All–Cause Mortality
Mechanical thrombectomy was associated with a trend toward reduced risk of all-cause mortality; the relative size of the data markers indicates
the weight of each study’s sample size. Abbreviations as in Figure 1.
TABLE 3 Summary E
Outcome
mRS 0–2
mRS 0–1
mRS 0–3
All-cause mortality
Recanalization
sICH
Recurrent stroke
*Values are presented for m
for Peto’s method.
CI ¼ conﬁdence interval
symptomatic intracranial h
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2502excellent (mRS 0 to 1) functional outcomes (26.3%
vs. 15.5%; RR: 1.67; 95% CI: 1.27 to 2.19; p <
0.0001), and fair (mRS 0 to 3) functional outcomes
(59.0% vs. 45.1%; RR: 1.32; 95% CI: 1.12 to 1.56;stimates for the Outcomes of Interest
Incidence (%)* Model RR† 95% CI p Value I2 (%)
43.7/30.9 DL 1.45 1.22–1.72 <0.0001 54
Peto 1.74 1.48–2.06 <0.0001 58
26.3/15.5 DL 1.67 1.27–2.19 <0.0001 47
Peto 1.78 1.44–2.21 <0.0001 48
59.0/45.1 DL 1.32 1.12–1.56 0.001 67
Peto 1.73 1.45–2.07 <0.0001 73
15.9/17.9 DL 0.86 0.72–1.02 0.09 0
Peto 0.82 0.67–1.02 0.08 0
66.6/39.2 DL 1.57 1.11–2.23 0.01 88
Peto 3.09 2.46–3.89 <0.0001 83
5.1/5.0 DL 1.06 0.73–1.55 0.76 0
Peto 1.02 0.69–1.52 0.92 0
5.0/2.8 DL 1.97 0.64–6.03 0.24 68
Peto 1.62 0.98–2.67 0.06 73
echanical thrombectomy/intravenous thrombolysis groups. †Odds ratio was reported
; DL ¼ DerSimonian and Laird; mRS ¼ modiﬁed Rankin scale; RR ¼ risk ratio; sICH ¼
emorrhage; other abbreviations as in Tables 1 and 2.p ¼ 0.001) compared with intravenous thrombolysis
alone (Online Figures 2 and 3). Recanalization rates
were reported by 6 trials (Online Table 1) (10,27–31).
Mechanical thrombectomy after usual care was
associated with improved recanalization compared
with usual care alone (66.6% vs. 39.2%; RR: 1.57;
95% CI: 1.11 to 2.23; p ¼ 0.01).
SAFETY OUTCOMES. The risk of in-hospital sICH
was similar between both arms (5.1% vs. 5.0%; RR:
1.06; 95% CI: 0.73 to 1.55; p ¼ 0.76) (Online
Figure 4). The risk of recurrent stroke at 90 days
was nonsigniﬁcantly higher with mechanical throm-
bectomy (5.0% vs. 2.8%; RR: 1.97; 95% CI: 0.64 to
6.03; p ¼ 0.24) (Online Figure 5). This was driven
predominantly by a higher embolic stroke rate in the
MR CLEAN trial (5.6% vs. 0.4%) (27). In a sensitivity
analysis, excluding MR CLEAN, the risk of recurrent
stroke was similar with both modalities (4.8% vs.
4.2%; RR: 1.10; 95% CI: 0.59 to 2.06; p ¼ 0.77).
No evidence of publication bias was observed for
any of the secondary or safety outcomes. Table 3
provides the summary estimates for the outcomes
of interest using the methods by DerSimonian and
Laird and Peto.
CENTRAL ILLUSTRATION Mechanical Thrombectomy in Stroke: Functional Outcomes and All-Cause Mortality
Elgendy, I.Y. et al. J Am Coll Cardiol. 2015; 66(22):2498–505.
In patients with acute ischemic stroke due to large artery occlusion, mechanical thrombectomy was associated with a signiﬁcantly higher
incidence of achieving good functional outcome, deﬁned as modiﬁed Rankin scale (mRS) 0 to 2, compared with usual care alone (p < 0.0001).
Those who had mechanical thrombectomy also had a higher incidence of excellent functional outcomes (mRS 0 to 1; p < 0.0001) and fair
functional outcomes (mRS 0 to 3; p ¼ 0.001), and a trend toward lower all-cause mortality (p ¼ 0.09). (Inset) Number needed to treat for the
functional outcomes.
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2503DISCUSSION
In this meta-analysis of 9 randomized trials with
2,410 patients with acute ischemic stroke caused by
large artery occlusion who presented within 4.5 h of
symptom onset, mechanical thrombectomy after
usual care was associated with improved recanali-
zation rates, better functional outcomes, and a
similar risk of sICH compared with usual care alone
(i.e., intravenous thrombolysis). In particular, me-
chanical thrombectomy after usual care was asso-
ciated with a 45% higher relative likelihood and
a 13% higher absolute likelihood of achieving a
good functional outcome at 90 days (mRS 0 to 2)
compared with usual care alone administered within
the recommended ischemic window (number needed
to treat ¼ 8) (Central Illustration). The metare-
gression analysis demonstrated that outcomes were
improved in the more recent studies (i.e., those that
used stent retrievers). In addition, there was a trend
for reduced all-cause mortality with mechanical
thrombectomy.
All studies included in this analysis showed a trend
for better outcomes with mechanical thrombectomy,except for MR RESCUE (26). In this study, the in-
vestigators had incorporated advanced imaging
before mechanical thrombectomy, resulting in a delay
in the time to recanalization (34). In the EXTEND-IA
(Extending the Time for Thrombolysis in Emergency
Neurological Deﬁcits–Intra-arterial), SWIFT PRIME
(Solitaire FR With the Intention for Thrombectomy as
Primary Endovascular Treatment for Acute Ischemic
Stroke), REVASCAT (Randomized Trial of Revascu-
larization with Solitaire FR Device versus Best Medi-
cal Therapy in the Treatment of Acute Stroke Due to
Anterior Circulation Large Vessel Occlusion Present-
ing within Eight Hours of Symptom Onset), and
THERAPY trials, functional perfusion imaging was
encouraged before randomization, yet investigators
emphasized workﬂow efﬁciency to speed up study
enrollment (29–32). Moreover, a strategy of advanced
imaging has not been shown to affect patient
outcomes or reduce the risk of intracerebral hemor-
rhage (35). Physical examination, along with non-
contrast computed imaging, might be sufﬁcient to
select appropriate patients for mechanical throm-
bectomy (36). The American Heart Association/
American Stroke Association recently gave a new 1A
PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: In patients with acute
ischemic stroke due to large artery occlusion who
present in the appropriate timeframe, mechanical
thrombectomy after intravenous thrombolytic
therapy is associated with better functional outcomes
than thrombolysis alone.
TRANSLATIONAL OUTLOOK: Further investiga-
tion is needed to identify speciﬁc characteristics of
patients with acute ischemic stroke who beneﬁt most
from mechanical thrombectomy.
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2504recommendation for endovascular treatment (in
particular stent retrievers) as an adjunctive therapy to
intravenous thrombolysis for patients with acute
ischemic stroke secondary to a clot in a major artery
and with evidence of salvageable brain tissue on
noninvasive imaging when presenting within 6 h of
symptom onset (37).
Intravenous thrombolysis remains the cornerstone
for acute ischemic stroke management; however,
<30% of eligible patients receive intravenous throm-
bolysis within the recommended time window (6,38).
Although mechanical thrombectomy is beneﬁcial,
this procedure requires specialized centers of ex-
cellence; therefore, the widespread application of
this therapy for acute ischemic stroke patients will
likely remain limited for the foreseeable future.
A recent report from the national Get With The
Guidelines-Stroke registry demonstrated that 41.8% of
participating hospitals were capable of providing
endovascular therapy to acute ischemic stroke pa-
tients (39). Future studies may need to explore the
beneﬁt of contemporary mechanical thrombectomy
alone among patients who are not pre-treated with
intravenous thrombolysis.
In the present analysis, we showed that mechani-
cal thrombectomy after usual care was associated
with a similar risk of sICH and recurrent stroke (in all
arterial territories). In the MR CLEAN trial, the risk of
recurrent stroke was signiﬁcantly increased with
mechanical thrombectomy, in contrast to other
studies. In MR CLEAN, the investigators deﬁned
recurrent stroke as new ischemic stroke in a different
vascular territory. In addition, a proportion of pa-
tients in the mechanical thrombectomy arm under-
went a simultaneous acute cervical carotid stenting
(i.e., second revascularization procedure) (27). Over-
all, our meta-analysis demonstrated that mechanical
thrombectomy for acute ischemic stroke patients is
relatively safe.
A recent meta-analysis demonstrated that endo-
vascular therapy was associated with improved
functional outcome with similar risk of mortality and
sICH compared with intravenous thrombolysis (40).
In the present analysis, we evaluated only the
studies that allowed intravenous thrombolysis before
mechanical thrombectomy (i.e., we excluded SYN-
THESIS Expansion [Local Versus Systemic Throm-
bolysis for Acute Ischemic Stroke] [12]). We also
assessed the beneﬁts of mechanical thrombectomy on
a wide spectrum of outcomes with the totality of the
available data, including the recently presented
studies THRACE (Trial and Cost Effectiveness Evalu-
ation of Intra-arterial Thrombectomy in Acute
Ischemic Stroke) and THERAPY (32,33).STUDY LIMITATIONS. The main outcome measure
selected for this analysis was mRS 0 to 2, which has
been used in all stroke trials. However, interobserver
variability in describing the mRS is a potential limita-
tion to the present study (41). Also, there was a sig-
niﬁcant degree of heterogeneity observed for several
outcomes in this analysis, which can be explained by
the variation in the study designs. We attempted to
mitigate this by using random effects models when
possible. Another limitation is the fact that some of the
studies are yet unpublished; thus, a sensitivity anal-
ysis for the main outcome excluded these trials. In
addition, we were not able to examine the impact of
symptom duration on mechanical thrombectomy;
however, 1 study delayed time to reperfusion due to
advanced imaging and tended to have worse
outcomes. Finally, lack of access to patient-level data
precluded a full evaluation to identify patient charac-
teristics and the National Institutes of Health Stroke
Scale associated with the maximal clinical beneﬁts.
CONCLUSIONS
In acute ischemic stroke patients with large artery
occlusion, mechanical thrombectomy after usual care
was associated with improved functional outcomes
compared with usual care alone (i.e., intravenous
thrombolysis) and is relatively safe, with no excess in
intracranial hemorrhage. There was a trend for
reduction in all-cause mortality with mechanical
thrombectomy.
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